You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196051 - 196060 of 207728 results
  1. Dual-action drug coated balloon to mitigate neointimal hyperplasia and promote endothelialization.

    SBC: ENDOMIMETICS LLC            Topic: NHLBI

    Project SummaryThe management of atherosclerotic vascular stenosis has undergone major advances over the past decades, yet challenges remain. Bare metal stents (BMS) were plagued by unacceptably high rates of in-stent restenosis (ISR). Although drug-eluting stents (DES) were developed primarily to reduce neointimal hyperplasia (NIH), rates of ISR remain at least 5-15%. Furthermore, the use of sten ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Exonuclease Based Microsatellite Sequencing

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 102

    Project Summary Electronic BioSciences (EBS) will investigate and develop methodologies to sequence microsatellite regions within the human genome to enable cancer genotyping via a true single-molecule, ultra-high-accuracy approach. Microsatellites are simple/short repeats (1-10 nucleotides in length) that occur in tandem 5-50 times and are among the most variable types of DNA sequence in the geno ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Split-luciferase Epigenetic Assays for Drug Discovery

    SBC: LUCEOME BIOTECHNOLOGIES, L.L.C.            Topic: 300

    Project Summary Epigenetic control is essential for maintaining transcriptional integrity. Regulation of the dynamic epigenome is mediated through a range of post translational modifications on DNA and histone tails. Histone modifications are mediated by enzymes which can be broadly classified into “writers” that catalyze the addition of chemical modifications, “erasers” that remove the mo ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Small Molecule N-myc Degraders as Novel Cancer Therapeutic Agents

    SBC: Stemsynergy Therapeutic            Topic: NCI

    ABSTRACT The MYC family proteins are comprised of three paralogs termed Myc (c-myc), N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. High levels of N-myc protein (gene name: MYCN) are often found in tumors of neuroendocrine origi ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Spatially Resolved, Multi-Omics Analyses of Immune Infiltrates in GBM Microenvironment

    SBC: ATLASXOMICS INC            Topic: NCI

    Abstract: In this SBIR grant, AtlasXomics Inc. proposes to develop a novel spatial immunophenotyping device that maps immune infiltrates in the mouse brain tumor microenvironment (TME) by spatially co-profiling ~20 immune surface protein biomarkers and the whole transcriptome (WT) with cellular resolution. In collaboration with researchers at the National Cancer Institute (NCI), we will demonstrat ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. 3D diagnosis of Hirschsprung disease using open-top light-sheet microscopy

    SBC: ALPENGLOW BIOSCIENCES, INC.            Topic: 300

    Abstract Hirschsprung disease is a congenital defect that affects an estimated 1:5000 liveborn infants. It is characterized by absent ganglion cells (neurons) in the distal rectum and a variable length of contiguous proximal bowel. The diagnosis of Hirschsprung disease relies upon subjective pathologist interpretation of up to 100 tissue sections from suction rectal biopsies to prove the absence o ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Theranostic NTSR1-targeting Agents for Complementary Management of PSMA-negative Prostate Cancer

    SBC: ACCUNOVO BIOTECHNOLOGIES INC            Topic: NCI

    Project Summary The long-term goal of this project is to develop a theranostic (for both diagnosis and therapy) agent targeting neurotensin receptor 1 (NTSR1) for prostate cancer management. Prostate cancer is the second-leading cause of cancer deaths for men in the United States. Approximately 1 in 9 men will be diagnosed with prostate cancer in their lifetime. Despite recent developments in its ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. High throughput single cell linear displacement adhesion assay

    SBC: NEUROINDX            Topic: 400

    ABSTRACT Cell adhesion is an essential process for any living cell. It is critical for cell differentiation, division, migration and specialization. Dysfunction of cell adhesion is a hallmark of various pathological phenotypes, including chronic kidney diseases, cancer, and many others. In the effort to discover new disease treatments and improve our basic understanding of single cell properties t ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Wiring Catheter for Crossing Complex Chronic Total Occlusions

    SBC: Minnesota HealthSolutions Corporation            Topic: NHLBI

    Project Summary/Abstract We propose to develop an innovative wiring catheter system to reliably direct subintimal crossing and re-entry into the artery true lumen during treatment of complex arterial chronic total occlusions (CTO). The proposed system will improve techniques for treating complex CTOs during percutaneous coronary and peripheral artery interventions (PCI). Atherosclerosis drives dev ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. High-throughput discovery platform for modulators of cardiac muscle proteins to treat heart failure

    SBC: Photonic Pharma LLC            Topic: NHLBI

    Project Summary This Phase I SBIR collaboration between Photonic Pharma LLC (PP) and the University of Arizona (UA) will establish proof-of-concept for an innovative drug-discovery campaign for treatment of heart failure (HF), targeting cardiac myosin-binding protein C (MyBP-C). There is an urgent need for novel therapies for HF, a major health problem affecting 1 in 30 adults in the US. MyBP-C ha ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government